Business
Moleculin Announces Interim Phase 2 Data in STS Clinical Trial and Update on Recruiting, Preliminary Efficacy and Expected Milestones for AML Clinical Trials
– Actively recruiting in three Phase 1b/2 clinical trials (with one now in Phase 2) and have recently concluded one trial – Reached 50% recruitment of Phase 2
About this update from Moleculin Biotech, Inc.
[{"type":"text","content":"– Actively recruiting in three Phase 1b/2 clinical trials (with one now in Phase 2) and have recently concluded one trial \n– Reached 50% recruitment of Phase 2 portion of soft tissue sarcoma (STS) lung metastases trial\n– Multiple expected milestones and interim data readouts expected in 2023 \nHOUSTON, March 22, 2023 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a growing pipeline, including Phase 2 clinical programs, for hard-to-treat cancers and viruses, today announced recent activity, new positive data and expected near term milestones across its clinical development pipeline.\n\n \n \n \n \n \n \n\n \n\"We continue to make significant progress on multiple fronts across our development pipeline and ongoing clinical trials. Our team believes that the human activity demonstrated with our lead program, Annamycin, in two separate indications, normally treated with doxorubicin (or its equivalent), continues to support our expectation of generating pivotal data in 2023. Additionally, preliminary data continue to demonstrate a promising safety and efficacy profile with zero evidence of cardiotoxicity, as analyzed by our independent expert, which bolsters our confidence in Annamycin's potential as we continue to advance development. Additionally, we are pleased with the rapid pace of enrollment in our Phase 2 STS lung metastases clinical trial that, we believe, has us on track to complete enrollment in the first half of 2023 and in a position to report topline data from this study in the second half of this year,\" commented Walter Klemp, Chairman and Chief Executive Officer of Moleculin.\nMr. Klemp added, \"2023 is poised to be an exciting year. We are actively recruiting in three Phase 1b/2 clinical trials and expect to add more trials during the year. These three currently active clinical trials are open label and provide us with the opportunity to announce clinical activity as it is being demonstrated throughout 2023. Additionally, in February 2023, our externally funded Phase 1 clinical trial studying WP1066 for the treatment of pediatric brain tumors concluded, and we expect to have at least three externally funded Phase 1b/2 clinical trials for WP1066 in the treatment of GBM and other brain tumors in 2023, including another pediatric clinical...